From: Clinical application of tumor volume in advanced nasopharyngeal carcinoma to predict outcome
Variables | Overall survival (RR, 95% CI) | p | Disease-specific survival (RR, 95% CI)) | p | Disease-free survival (RR, 95% CI) | p | Loco-regional control (RR, 95% CI) | p | Distant metastasis-free survival (RR, 95% CI) | p |
---|---|---|---|---|---|---|---|---|---|---|
T1-2 vs. T3-4 | 1.29, 0.56-2.98 | 0.56 | 1.42, 0.41-4.86 | 0.58 | 0.85, 0.34-2.16 | 0.73 | 1.44, 0.27-7.64 | 0.67 | 1.00, 0.36-2.81 | 1.00 |
N0-2 vs. N3 | 2.47, 0.48-12.71 | 0.28 | 1.86, 0.15-23.26 | 0.63 | 2.85, 0.53-15.18 | 0.22 | 39.06, 1.55-983.27 | 0.03 | 2.77, 0.54-14.07 | 0.22 |
Cranial nerve involvement | 0.71, 0.26-1.95 | 0.51 | 0.73, 0.17-3.13 | 0.67 | 0.65, 0.18-2.28 | 0.50 | 0.11, 0.006-2.10 | 0.14 | 0.95, 0.26-3.46 | 0.94 |
Supraclavicular nodes | 0.74, 0.15-3.74 | 0.71 | 0.78, 0.06-9.59 | 0.85 | 0.45, 0.08-2.50 | 0.36 | 0.02, 0.001-0.87 | 0.04 | 0.68, 0.13-3.43 | 0.64 |
GTVprn (13 ml) | 2.92, 1.22-6.98 | 0.02 | 4.10, 1.06-15.97 | 0.04 | 4.81, 1.73-13.36 | < 0.01 | 16.83, 1.48-190.78 | 0.02 | 2.50, 0.84-7.43 | 0.10 |